The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 41.50
Bid: 40.00
Ask: 43.00
Change: 0.00 (0.00%)
Spread: 3.00 (7.50%)
Open: 41.50
High: 41.50
Low: 41.50
Prev. Close: 41.50
FIPP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Agreement with FCT, Universidade NOVA de Lisboa

14 Sep 2016 11:50

RNS Number : 8333J
Frontier IP Group plc
14 September 2016
 

AIM: FIPP

14 September 2016

 

Frontier IP Group Plc

("Frontier IP" or the "Group")

 

Agreement with the Faculty of Science and Technology of Universidade NOVA de Lisboa

 

Frontier IP, which specialises in the commercialisation of intellectual property, is pleased to announce that it has today signed an agreement with the Faculty of Science and Technology within the Universidade NOVA de Lisboa, Portugal ("FCT NOVA") to assist with its spin-off and licensing activities emerging from its research programmes. This partnership is Frontier IP's second in Portugal and reflects the Group's view that there is significant opportunity in the region.

 

The Universidade NOVA de Lisboa is a research-intensive university (QS Top Universities 2016) and FCT NOVA, its engineering school, has particular research strengths in Materials, Environment, Energy, Biotechnology, Conservation and Restoration. Frontier IP and FCT NOVA will work together to maximise the commercial value of intellectual property developed within or owned by FCT NOVA. Frontier IP will receive a share of equity in each spin-off company created by FCT NOVA, as well as a share in the licensing revenue it receives.

 

FCT NOVA is an active research collaborator, both within Portugal and internationally, and its partners include Massachusetts Institute of Technology (MIT), the University of Carnegie Mellon and the University of Texas at Austin, amongst others. The collaboration with Frontier IP aims to accelerate value creation from the research generated within FCT NOVA and provide access to early stage funding, commercialisation expertise and a wider network of industrial partners.

 

The signing of the agreement was attended by Her Majesty's Ambassador to the Portuguese Republic, Mrs Kirsty Hayes. Addressing the audience, the Ambassador emphasised the importance of effective commercialisation of the intellectual property being generated through the investment in research and development in Portugal's universities. The UK has strong experience of intellectual property commercialisation and it has been a principle focus for British universities to develop a portfolio of intellectual property which has relevance to the business world.

 

Her Majesty's Ambassador to the Portuguese Republic, Mrs Kirsty Hayes, said:

 

"I am delighted by the announcement of this important agreement between Frontier IP and FCT NOVA, which will drive the commercialisation of intellectual property from one of the leading Portuguese universities, which has a strong reputation for investment in research and development. This agreement represents a further strengthening of collaboration between Portugal and the United Kingdom."

 

Neil Crabb, Chief Executive of Frontier IP, said:

 

"We are delighted that FCT NOVA has chosen us as its commercialisation partner. This agreement gives us access to FCT NOVA's excellent research base and builds on the strong relationships with the industrial partners and academic institutions which we have already established in the region. We are looking forward to working with FCT NOVA to further develop and commercialise its strong intellectual property portfolio."

 

Dr. Fernando Santana, Director of FCT NOVA, said:

 

"Frontier IP has a strong reputation in the commercialisation of university-based technologies. We hope that this agreement will bring increased international visibility to FCT NOVA's portfolio, making it an even more successful institution by maximizing the impact of its knowledge. This shows FCT NOVA's commitment to innovation, which benefits the institution and the wider society it serves."

 

Enquiries

 

Frontier IP Group Plc

 

T: 0131 240 1251

Neil Crabb, Chief Executive

 

 

Company website: www.frontierip.co.uk

 

 

 

Cantor Fitzgerald Europe

(Nominated Adviser and Joint Broker)

 

T: 020 7894 7000

David Foreman, Catherine Leftley, Corporate Finance

 

 

David Banks, Sales

 

 

 

 

 

Peterhouse Corporate Finance Limited

(Joint Broker)

 

T: 020 7469 0935

Lucy Williams

 

 

 

 

 

Kreab

 

T: 020 7074 1800

Robert Speed, Matthew Jervois

 

 

 

 

Notes to Editor:

 

About Frontier IP Group plc

www.frontierip.co.uk 

Frontier IP specialises in assisting institutions and companies in the commercialisation and exploitation of their intellectual property. It establishes formal and informal relationships with sources of exploitable IP, principally universities. Its core business is building and growing a portfolio of equity stakes in spin-out companies by taking an active involvement in the commercialisation and funding of these businesses.

 

About Universidade NOVA de Lisboa, Faculty of Science and Technology

http://www.fct.unl.pt

FCT NOVA is one of the most prestigious Portuguese engineering and science public schools and it is engaged in extensive research activity developed in 16 research centres involving 1600 PhD and Master's students and a total of 550 academic staff (90% holding a Ph.D). FCT NOVA partners with foreign universities such as the Massachusetts Institute of Technology (MIT), the University of Carnegie Mellon and the University of Texas at Austin to offer some of its advanced study programs. The entrepreneurial drive of the students and graduates of FCT NOVA has led to many successful spin-offs that transfer knowledge to the market and help create value and social impact.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRLLFSIARISLIR
Date   Source Headline
7th May 202410:15 amRNSTVG to collaborate with The Pirbright Institute
2nd May 20247:00 amRNSFrontier IP announces stake in DiaGen
17th Apr 20241:59 pmRNSHolding(s) in Company
12th Apr 20247:00 amRNSAppointment of Chief Financial Officer
2nd Apr 202412:44 pmRNSHolding(s) in Company
14th Mar 20247:00 amRNSUnaudited Half Year Results
4th Mar 20241:40 pmRNSHolding(s) in Company
29th Feb 20243:12 pmRNSSale of shares in Exscientia
30th Jan 202411:45 amRNSHolding(s) in Company
22nd Jan 20247:00 amRNSOctopus invest in Alusid as part of equity funding
29th Dec 202312:00 pmRNSTotal Voting Rights
19th Dec 20234:46 pmRNSHolding(s) in Company
15th Dec 20236:12 pmRNSReplacement - Result of AGM and Directorate Change
15th Dec 20232:07 pmRNSResult of AGM and Directorate Change
13th Dec 20237:00 amRNSPortfolio news - The Vaccine Group
11th Dec 20237:00 amRNSHolding(s) in Company
30th Nov 20235:00 pmRNSTotal Voting Rights
30th Nov 20237:00 amRNSExercise of Options & Director/PDMR Shareholdings
28th Nov 20237:00 amRNSBoard Change
21st Nov 20237:00 amRNSPosting of Annual Report and Notice of AGM
9th Nov 20235:27 pmRNSHolding(s) in Company
3rd Nov 20237:05 amRNSGrant of options
1st Nov 20235:48 pmRNSExercise of Options & PDMR Shareholdings & TVR
31st Oct 20237:01 amRNSBoard changes
31st Oct 20237:00 amRNSFinal results for the year ended 30 June 2023
23rd Oct 20237:00 amRNSNew portfolio company Deakin Bio-Hybrid Materials
12th Oct 20232:05 pmRNSHolding(s) in Company
21st Sep 20237:00 amRNSExscientia announces collaboration with Merck
14th Sep 20235:21 pmRNSHolding(s) in Company
14th Sep 20237:00 amRNSExercise of Options & Total Voting Rights
11th Sep 20237:00 amRNSPortfolio news – Pulsiv appoints Chairman and CPO
8th Sep 20237:00 amRNSExercise of Options & Total Voting Rights
10th Aug 20238:45 amRNSPortfolio news – Fieldwork Robotics
24th Jul 20237:00 amRNSPortfolio news – CamGraPhIC loan facility
20th Jul 20235:18 pmRNSHolding(s) in Company
1st Jun 20237:00 amRNSSale of shares in Exscientia
26th May 20236:06 pmRNSHolding(s) in Company
9th May 20237:00 amRNSTopps Tiles launches first Alusid made tile range
21st Apr 20234:00 pmRNSDirectorate Change
20th Apr 20235:26 pmRNSHolding(s) in Company
27th Mar 20235:17 pmRNSHolding(s) in Company
17th Mar 20232:46 pmRNSGrant of options
15th Mar 20237:00 amRNSBoard changes
15th Mar 20237:00 amRNSUnaudited Half Year Results
30th Jan 20237:00 amRNSAlusid in collaboration with Imerys
9th Jan 20237:00 amRNSCelerum appoints David Gladding as CEO
9th Dec 20224:08 pmRNSResult of AGM
7th Dec 20221:25 pmEQSThe Vaccine Group completes two deadly disease vaccination projects
6th Dec 20227:00 amRNSFrontier IP to host Portfolio Demo Day
5th Dec 20227:00 amRNSThe Vaccine Group completes Lassa fever project

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.